Immuto Scientific is a biotechnology startup, founded in 2018, with a mission to revolutionize the discovery of biotherapeutics. The company's proprietary technologies allow for unparalleled protein structural analysis, enhancing the drug discovery process by facilitating precise assessment of drug binding, target conformation, and interactions at an exceptional speed and accuracy.
With a focus on enabling the development of next-generation therapeutics against challenging targets, Immuto Scientific is committed to demystifying and democratizing protein structure, function, and dynamics. The company's innovative approach has attracted $100.00K in grant investment from SBIR Advance as of 14 December 2022.
Headquartered in the United States, Immuto Scientific's advancements in structure-based platform technology hold the potential to significantly impact the biotechnology and pharmaceutical industries, offering a promising opportunity for investors seeking to participate in the forefront of rational drug design and reimagined drug discovery.